# Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care

> **NIH NIH U01** · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2024 · $505,996

## Abstract

Abstract
Cervical cancer is among the leading causes of cancer death in women worldwide, especially in low- and middle-
income countries (LMICs). High-risk human papillomaviruses (HPV) are the main causative agents of cervical
cancer and its precursor lesions; therefore, the World Health Organization (WHO) has recommended HPV DNA
testing for cervical cancer screening in LMICs. Although polymerase chain reaction (PCR) methods have been
widely used for HPV DNA detection, they are restricted to centralized clinical laboratories due to the need for
labor-intensive procedures and expensive equipment. Here, we propose to develop a simple, rapid, highly
sensitive, and specific CRISPR-on-paper diagnostic platform to simultaneously detect multiple high-risk HPV
genotypes for cervical cancer screening at the point of care. This innovative diagnostic system is based on our
recently developed all-in-one dual CRISPR-Cas12a (AIOD-CRISPR) assay, which combines the simplicity and
high sensitivity of isothermal nucleic acid amplification with the high specificity of CRISPR detection. To develop
a low-cost, multiplexed molecular detection technology, we will incorporate the AIOD-CRISPR assay into a
paper-based microfluidics platform. To eliminate the need for complex electronic instruments, we will take
advantage of an exothermic reaction to generate chemical heat for the CRISPR-on-paper system by using a
disposable hand warmer, thus enabling instrument-free cervical cancer screening. The detection results can be
read by the naked eye or reported by a programmed smartphone without the need for an expensive optical
detector. We will rigorously evaluate and validate the clinical applications of our CRISPR-on-paper diagnostic
system by testing clinical samples in collaboration with clinicians and healthcare workers in UConn Health and
Zambia. If successful, the proposed project has an important impact on global health by providing a simple,
affordable, and sensitive method for rapid screening of cervical cancer in resource-poor settings. As a platform
technology, the proposed CRISPR-on-paper diagnostic system can be easily adapted to detect other emerging
pathogens.

## Key facts

- **NIH application ID:** 10834047
- **Project number:** 5U01CA269147-03
- **Recipient organization:** UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
- **Principal Investigator:** Changchun Liu
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $505,996
- **Award type:** 5
- **Project period:** 2022-05-01 → 2027-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10834047

## Citation

> US National Institutes of Health, RePORTER application 10834047, Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care (5U01CA269147-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10834047. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*